Lon­nel Coats an­nounces re­tire­ment from Lex­i­con; An­oth­er shake­up in Vir's C-suite

→ Lex­i­con Phar­ma­ceu­ti­cals CEO Lon­nel Coats will re­tire Ju­ly 7, 10 years to the day af­ter ac­cept­ing the job. Lex­i­con over­came nu­mer­ous reg­u­la­to­ry ob­sta­cles with its SGLT1/2 in­hibitor so­tagliflozin to earn an FDA ap­proval for heart dis­ease on May 26, 2023, and the treat­ment is now mar­ket­ed as In­pe­fa. Lex­i­con is giv­ing it an­oth­er go with the drug in type 1 di­a­betes fol­low­ing an FDA re­jec­tion in this in­di­ca­tion; the biotech’s at­tempts to re­verse the CRL al­so fell short. Sanofi backed out of its al­liance with Lex­i­con af­ter the FDA ver­dict on so­tagliflozin.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER